Sign Up
You are not currently logged in. Please log in to CEUfast to enable the course progress and auto resume features.

Course Library

Controlled Substance Prescribing: Tennessee Requirements

2 Contact Hours including 2 Pharmacology Hours
Meets Tennessee Requirements
Listen to Audio
CEUfast OwlGet one year unlimited nursing CEUs $39Sign up now
This peer reviewed course is applicable for the following professions:
Advanced Practice Registered Nurse (APRN), Certified Nurse Midwife, Certified Nurse Practitioner, Certified Registered Nurse Anesthetist (CRNA), Certified Registered Nurse Practitioner, Clinical Nurse Specialist (CNS), Licensed Practical Nurse (LPN), Licensed Vocational Nurses (LVN), Midwife (MW), Nursing Student, Registered Nurse (RN), Registered Nurse Practitioner
This course will be updated or discontinued on or before Thursday, March 23, 2028

Nationally Accredited

CEUFast, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. ANCC Provider number #P0274.


Outcomes

≥ 92% of participants will know how to incorporate both pharmacologic and non-pharmacologic therapies into a comprehensive, patient-centered plan for chronic pain.

Objectives

After completing this course, the learner will be able to:

  1. Identify the risks of misuse, abuse, and addiction associated with controlled substances.
  2. Describe the key elements of a comprehensive pain assessment and methods to evaluate therapeutic outcomes.
  3. Apply evidence-based principles and Tennessee regulatory requirements for the safe and effective prescribing of controlled substances.
  4. Specify appropriate risk-mitigation strategies to promote patient safety.
  5. Compare pharmacologic and non-pharmacologic pain management modalities to support individualized, patient-centered care.
CEUFast Inc. and the course planning team for this educational activity do not have any relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Last Updated:
  • $39 Unlimited Access for 1 Year
    (Includes all state required Nursing CEs)
  • No Tests Required
    (Accepted by most states & professions)
  • Instant Reporting to CE Broker
  • Instant Access to certificates of completion
Logo Audio
Now includes
Audio Courses!
Learn More
Restart
Restart
  • 0% complete
Hide Outline
Playback Speed

Narrator Preference

(Automatically scroll to related sections.)
Done
Controlled Substance Prescribing: Tennessee Requirements
0:00
0:15
 
To earn a certificate of completion you have one of two options:
  1. Take test and pass with a score of at least 80%
  2. Reflect on practice impact by completing a course evaluation.
    (NOTE: Some approval agencies and organizations require you to take a test and the course evaluation is NOT an option.)
Author:    Krystle Maynard (DNP, RN, SANE-A)

Introduction

Pain may show up in many forms, and most people experience it at some point in their lives. Acute pain usually has an easily justifiable cause, such as an injury, surgery, or illness. Acute pain will often improve as the body heals. Chronic pain is different. It lingers past the expected recovery time and can affect how a person moves, sleeps, and functions day to day. It often becomes more than a physical symptom and starts to influence mood, stress levels, and overall quality of life. Because pain is rarely one-dimensional, understanding the type, cause, and impact is the first step toward choosing the right treatment plan.

Pain looks different for every individual, and effective management requires more than simply choosing a medication. It involves careful assessment, awareness of mental health factors, and an understanding of the risks tied to certain medications. In this course, expect to navigate the essentials of safe prescribing, explore both pharmacologic and non-pharmacologic treatment options, and gain tools that help providers make safer, more informed decisions in everyday practice.

Understanding Pain and Its Assessment

The Joint Commission (TJC) expects healthcare providers to assess, manage, and monitor pain as part of routine, safe patient care. Accredited organizations must have clear policies on how pain is assessed, what treatment options are available, how staff are trained, and how those interventions are evaluated (TJC, 2021).

Providers (and nursing staff) are expected to check and document pain across all care settings. This includes:

  • When a patient first arrives on the unit, and during their initial assessment.
  • Anytime a patient has a procedure.
  • Whenever a patient reports new or changing pain.
  • After giving any pain medication, with a follow-up reassessment and documentation.

Pain itself is subjective, meaning that what one individual may rate their pain as a "2," another might rate theirs an "8." Because of that, providers are expected to rely on the individual's own description. Pain thresholds, tolerance, and what helps relieve pain can vary widely between people. Past experiences, cultural background, emotional state, and the environment can all influence how someone perceives pain (Stretanski et al., 2025).

Since we cannot measure pain with a lab test or a monitor, standardized tools are used to support assessment findings. The Numeric Rating Scale (NRS) and the Wong-Baker FACES scale are two of the most common. They help providers and nursing staff track changes over time and evaluate whether an intervention is actually helping (Stretanski et al., 2025).

Numerical Rating Scale

The NRS is the most commonly used pain scale. It is the one where an individual is asked to rate their pain from 0 to 10. A 0 means no pain, and a 10 means the worst pain they can imagine.

While it is a simple tool, it comes with some challenges. The number an individual gives is based completely on their own perception, so it is not consistent from one person to another. Someone may call their pain a "3," while another person with the same level of discomfort calls it an "8." Even in the same individual, the number can shift from one assessment to the next. Because of this, using these numbers to guide treatment or medication orders can be tricky, since the score is not something that can be measured or verified in an objective way (Stretanski et al., 2025).

Wong-Baker FACES Pain Rating Scale

Individuals who are cognitively intact but unable to communicate clearly can use the Wong-Baker FACES scale to show how much pain they are in. The scale moves from a neutral or "smiling" face for no pain to progressively more distressed faces as pain increases. The individual points to the face that best reflects how they feel.

When someone cannot express their pain well, their pain is often missed or undertreated. This is where nursing assessment becomes essential. Nurses play a key role in noticing changes, interpreting what the individual is trying to communicate, and making sure their pain is addressed appropriately (Stretanski et al., 2025).

Image 1: Baker FACES Pain Rating Scale

photo of baker faces pain rating scale

Patient education is a big part of providing safe and quality care. Pain should be discussed before procedures, as well as pain control options and assessment tools being used. Proper education on the front end could promote better pain evaluations and reporting.

Pain Assessment

A thorough pain assessment should include all of the following information (Stretanski et al., 2025):

  1. Location: Where is the pain located, and does it radiate or spread anywhere else?
  2. Intensity: How intense is the pain at its worst and best?
  3. Character or quality: How someone describes their pain can help providers guide management strategies. For example:
    • Somatic (musculoskeletal) pain is typically localized and described as dull, aching, or sore.
    • Visceral pain tends to be poorly localized and may be described as cramping or squeezing.
    • Neuropathic (nerve) pain is often characterized as burning, shooting, or sharp, like a knife.
  4. Timing and pattern: Providers should assess the onset of pain, how long it lasts, and if there is any variation.
  5. Alleviating factors: Does anything help improve the pain? Examples may include repositioning, cool or warm compress, elevation, medication, etc.
  6. Aggravating factors: Does anything make the pain worse?
  7. Impact on daily life: How does the pain impact activities of daily living, quality of life, sleep, etc.?

Review of Medical History

Before making a plan of care, prescribers should review each individual's medical history. This includes looking at what has or has not worked in the past, looking at past medical records, labs, imaging, and more. All of this can help providers determine what has or has not worked and what they believe may be helpful moving forward.

If someone has past medical conditions, such as renal insufficiency, this can make treatment options more challenging. Renal insufficiency is one condition where there can be variations in how well certain medications are processed and metabolized within the body.

Prescribers are also expected to conduct a mental health assessment in their evaluation. Comorbid cognitive or mood disorders may impact pain control in certain individuals. Similarly, providers must also assess for any history of substance misuse or abuse tendencies (Tennessee Department of Health, 2024).

Physical Assessment

A physical assessment is also important when assessing an individual's pain. It gives the provider a starting point and helps identify anything unusual. During the exam, the provider watches how the individual moves—things like guarding, stiff posture, or trouble walking can tell a lot about where the pain is coming from.

The provider also checks for redness, swelling, any obvious deformities, or changes in temperature in the area. An abdominal exam may be needed if there is any concern for tenderness or bloating. Joints are checked to see how much range of motion there is and whether movement increases the pain (Tennessee Department of Health, 2024).

Diagnostic Tests

Depending on the description of the pain and the pain assessment, providers may opt to order diagnostic studies or imaging to help look for possible causes of pain. Common laboratory tests that can point toward inflammation or pain may include elevated inflammatory markers, such as C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR). Imaging examples may include X-rays, computed tomography (CT), and magnetic resonance imaging (MRI). Less commonly, electrodiagnostic studies may be ordered, such as nerve conduction tests or electromyography (EMG) (Rahman et al., 2023).

Controlled Substances

Controlled substances refer to any form of medication, preparation, or compound that belongs to scheduled classes I through V.

The controlled substance schedules are reviewed annually and updated, as needed. Included in this review is determining their potential for drug misuse or abuse. Providers are expected to be well-versed in the various types of pharmaceuticals, as well as their risks and benefits. Responsible prescribing helps reduce adverse outcomes and promote patient safety.

Prescription opioids are well-known controlled substances, and their misuse is known to burden healthcare systems and society as a whole. Individuals may decide to take medications inappropriately or try to sell or distribute substances to others. This is known to be a contributing factor to the suspected increase in addiction and overdose rates. Providers who conduct thorough assessments can help reduce these risks.

Prescribers need solid, practical education to keep patients safe and reduce medication misuse. Making high-quality, evidence-based training more accessible is one of the most effective ways to close knowledge gaps and support safer prescribing (Lopez et al., 2023).

Controlled Substances Act

The Controlled Substances Act is updated each year through the United States Drug Enforcement Administration (DEA) and is in place to regulate and control substances. The schedule classes are as follows (Lopez et al., 2023):

  • Schedule I substances have no accepted medical use in the United States. Examples may include heroin and lysergic acid diethylamide.
  • Schedule II and IIN substances may lead to physical or psychological dependence. Common substances may include oxycodone, hydrocodone, fentanyl, methadone, hydromorphone, morphine, opium, and codeine.
  • Schedule III and IIIN substances may include buprenorphine and medications containing less than 90 milligrams (mg) of codeine per dosage unit, such as Tylenol with Codeine. Schedule IIIN drugs also include anabolic steroids and ketamine.
  • Schedule IV substances have a lower risk of dependence than Schedule III drugs. Examples include benzodiazepines, midazolam, tramadol, and carisoprodol.
  • Schedule V substances have a low risk for abuse when compared to Schedule IV. They commonly include cough medications with small amounts of codeine, such as Robitussin AC.

Most controlled substances can impact the central nervous system (CNS). This can cause substances to affect mood, perception, or cognition. While some substances may be abused if they produce a euphoric feeling, misuse is still common for others. For example, if other medications affect sleep, anxiety, pain, and impact mood, it makes sense that some may choose to misuse these substances.

Advanced Practice Registered Nurses and Controlled Substance Prescribing

The Tennessee Board of Nursing (BON) regulates advanced practice registered nurses (APRNs) on their ability to prescribe controlled substances for the purpose of treating pain. The BON recognizes that pain is very subjective and that all advanced practice providers are expected to utilize sound judgment and critical thinking when opting to prescribe a controlled substance. Disciplinary action can occur if APRNs are found to be negligent or practice outside of their scope. The following are needed to be in place to allow APRNs to prescribe controlled substances for pain (Tennessee Board of Nursing, 2024):

  • Active advanced practice license.
  • Certificate of fitness by the BON.
  • Drug Enforcement Administration (DEA) registration certificate.
  • Conduct a thorough assessment and evaluation to determine the medical necessity.
  • Written treatment plan.
  • Documented pain history, history of or potential for substance abuse, comorbidities, and any pertinent assessments by other practitioners.
  • Educate on the risks and benefits of prescribing the controlled substance.
  • Regular re-evaluations and updated clinical necessity.

To avoid potential disciplinary action, the BON will monitor APRN prescription practices. In the event that disciplinary action is deemed necessary, APRNs could face educational program requirements, limited prescriptive authority, civil penalty, or more (Tennessee Board of Nursing, 2024).

Tennessee Board of Nursing

The Tennessee BON has a very clear position on controlled substances. The Tennessee BON acknowledges that controlled substances may be necessary for pain management, as long as they are prescribed and managed safely and effectively.

As long as APRNs follow prescribing guidelines, the risk of disciplinary action will be low. One of the expected guidelines is that prescribers must always perform a thorough physical assessment, including obtaining a medical history. Prescribers must also review any previous substance use, assess psychological status, and follow up with adequate documentation. Prescribers have to ensure that their documentation supports their assessment findings and that, before they prescribe a controlled substance, a legitimate source of pain has been identified and documented.

In the event a nurse practitioner were to ever deviate from the necessary guidelines, disciplinary actions could be possible, which may include a reprimand, opioid continuing (mandatory) education, prescription restrictions, civil penalties, and more. Penalties may increase in severity if guideline violations are repetitive (Tennessee Department of Health, 2024).

Tennessee Chronic Pain Guidelines

The Tennessee Department of Health established clinical practice guidelines for the outpatient management of chronic non-cancer pain (Tennessee Department of Health, 2024).

Key Principles of Prescribing

Tennessee developed chronic pain guidelines that outline several important directives for safe opioid prescribing (Tennessee Department of Health, 2024):

  • Having a previous opioid prescription does not justify continued prescribing.
  • Non-opioid therapies should always be trialed and implemented first.
  • All pregnant women should have regular urine drug screening.
  • When prescribing opioids to women of childbearing age, ensure that providers are discussing contraception to prevent unintended pregnancy.
  • A thorough evaluation and documentation must support the decision to prescribe opioids.
  • Telemedicine should not be utilized for prescribing pain medication.

Before prescribing controlled substances, providers should (Tennessee Department of Health, 2024):

  • Conduct a detailed medical history, including a thorough pain assessment.
  • Assess for other medical and mental health conditions.
  • Perform a comprehensive physical examination.
  • Screen for any history of substance use disorder.
  • Review previous medical records.
  • Evaluate women of childbearing age for pregnancy and ensure a documented diagnosis that supports opioid use.

An expectation for women of childbearing age is that, should she become pregnant while on opioid therapy, she should immediately notify her healthcare provider. Continuing opioid treatment during pregnancy requires education about the risks and benefits, as well as informed consent. Abrupt discontinuation without medical supervision can lead to preterm delivery, relapse, fetal distress, intrauterine withdrawal, or fetal death. Pregnant patients who remain on therapy should be co-managed by an obstetrician, pain specialist, or medication-assisted treatment program.

Providers should always evaluate for the potential of misuse or abuse prior to prescribing opioids. Common screening tools may include the Brief Risk Interview (BRI), Diagnosis, Intractability, Risk, Efficacy (DIRE) Score, Opioid Risk Tool (ORT), Pain Medication Questionnaire (PMQ), and the Screener and Opioid Assessment for Patients with Pain (SOAPP).

All individuals seeking to obtain a controlled substance should submit a urine drug screen to identify controlled or illicit substances, and providers should review the Controlled Substance Monitoring Database to assess previous prescription patterns (Tennessee Department of Health, 2025).

Pain management treatment goals should be clearly defined and focused on improving function and reducing pain, rather than completely eliminating it. The Pain, Enjoyment of life, and General Activity (PEG) assessment tool helps track treatment response by evaluating:

  • Average pain over the past week.
  • How pain affects the enjoyment of life.
  • How pain impacts general activity.

Mental Health

When assessing someone for pain management, it is important to look beyond the physical exam and the Controlled Substance Monitoring Database. Mental health can play a big role in how people experience pain and how well treatments work. The Tennessee Chronic Pain Guidelines recommend using screening tools to help identify concerns such as depression or mood changes. Common tools include the Patient Health Questionnaire-2 (PHQ-2) or Patient Health Questionnaire-9 (PHQ-9), the Hamilton Depression Rating Scale, and the Zung Self-Rating Depression Scale. These tools give providers a quick snapshot of a patient's emotional well-being and help guide safer, more effective treatment decisions (Brown & Bruns, 2020).

Emergency Department

Staff in an emergency department are not excluded from the prescribing guidelines. While chronic pain management should typically be coordinated through one provider, individuals may present to the emergency department for pain exacerbations. In these cases, intravenous or intramuscular opioids are generally not recommended for managing chronic pain flare-ups (Chang et al., 2021).

Providers in the emergency department also should not replace lost or stolen prescriptions or prescribe methadone or other long-acting opioids. When treating an acute exacerbation of pain, providers are encouraged to communicate with the patient's primary opioid prescriber and, if necessary, provide only enough medication to bridge care until the primary provider is available (Chang et al., 2021).

For new or acute injuries, opioid prescriptions should be limited to no more than three days, and all patients should be screened for potential substance use disorder before any opioid is prescribed (Chang et al., 2021).

When initiating opioid therapy, providers should:

  • Screen for pregnancy prior to prescribing.
  • Assess personal and family history of substance use disorders.
  • Evaluate mental health and behavioral factors that could influence safe use.
  • Refer complex cases (chronic pain, psychiatric comorbidities, or severe illness) to a pain specialist when appropriate.
  • Review current medications, particularly benzodiazepines or other sedatives that increase overdose risk.
  • Begin with a short-acting opioid trial, monitoring closely for pain relief, cognitive effects, and functional improvement.
  • Educate patients on secure storage (preferably locked), the importance of not sharing medications, and proper disposal of unused or expired prescriptions.

To reduce opioid misuse, Tennessee provides 82 secure medication drop boxes located across the state, many within local police departments. Additionally, Take-Back Events offer one-day opportunities for safe disposal and community awareness of opioid misuse (Tennessee Department of Health, 2024).

Opioid Treatment Agreements

Given the risks and side effects of opioids, providers should always establish a treatment agreement, which would then become a vital part of the individual's medical record. This agreement should include:

  • Goals of both the individual and the provider for pain control.
  • If they get pain under control, the goals are to begin tapering doses, if indicated.
  • Assessment of their overall quality of life and how pain management and other options may improve this.
  • Clear expectations and policies regarding prescriptions from other providers.

All of the steps listed here help hold providers and individuals accountable with realistic expectations to guide safe treatment and help prevent misuse of substances (Tennessee Department of Health, 2024).

Opioids

Opioid use is not uncommon in acute clinical settings. Previously, opioid medications were prescribed for cancer-related pain and for severe pain, with an acute rationale; chronic pain has become a more frequently prescribed reason for medication management. According to experts, evidence demonstrates a positive response to opioids in acute pain situations, but there is reason for concern for chronic use, in terms of the potential for misuse, overdose, and dependence.

The opioid class of medication was designed to bind to opioid receptors within the spinal cord and brain. These receptors are often termed Kappa, Mu, and Delta. Mu receptors have been said to carry the highest risk for dependence, but also provide the best pain relief. Both the Kappa and Delta receptors have been studied to improve pain by affecting the descending pain and periaqueductal gray pathways (Volkow & Blanco, 2021).

Morphine

Morphine is commonly referred to as a reference standard among opioid medications, used for comparison when reviewing the potency and effects of other opioids. Morphine can be administered through several routes, including oral, rectal, intravenous (IV), subcutaneous, and intramuscular (IM) (Ofoegbu & Ettienne, 2021).

Indications and Dosing

Morphine is often prescribed for moderate to severe acute pain and chronic severe pain, most commonly seen in an inpatient acute setting. It is available in multiple formulations, including tablets, oral solutions, suppositories, and injectable forms (Murphy et al., 2025).

  • Immediate-release tablet: 15–30 mg orally every four hours as needed
  • Oral solution: 10–20 mg every four hours as needed
  • Rectal suppository: 10–20 mg every four hours as needed

Common Side Effects

Common side effects of morphine are similar to other opioid analgesics and may include (Murphy et al., 2025):

  • Dry mouth
  • Constipation
  • Bradycardia and hypotension
  • Nausea and vomiting
  • Drowsiness or dizziness
  • Changes in mental status
  • Fever or itching
  • Weakness or hypoxia
  • Urinary retention

Contraindications

Morphine should not be given to patients with:

  • Known hypersensitivity or allergy to morphine
  • Severe or acute asthma
  • Paralytic ileus
  • Significant respiratory depression

Drug Interactions

Several medications can alter the effectiveness or safety of morphine (Murphy et al., 2025):

  • Amphetamines: May potentiate morphine's effects.
  • Anticholinergic agents: Can worsen constipation and urinary retention.
  • Antipsychotics: Increased risk of hypotension.
  • Azelastine (nasal): Increases CNS depression.
  • Clopidogrel: Reduced therapeutic efficacy when given together.
  • Diuretics: Increased risk of side effects.
  • Hydrocodone, hydroxyzine, and zolpidem: All can increase CNS depression.
  • Monoamine oxidase inhibitors (MAOIs): Increase morphine's side effects.
  • Selective serotonin reuptake inhibitors (SSRIs): May increase serotonergic effects and CNS depression.

Morphine continues to be used in pain management but requires careful consideration of dosing, contraindications, and potential drug interactions to ensure safe and effective use.

Fentanyl

Fentanyl is another strong synthetic opioid that can be given multiple different ways, including injection, transdermal patch, oral lozenge, sublingual tablet or spray, buccal tablet or film, and nasal spray. The transdermal patch is often prescribed for patients reporting moderate to severe chronic pain and who have a higher tolerance level. It is typically initiated at 25 micrograms (mcg)/hour and replaced every 72 hours (Ramos-Matos et al., 2023).

Indications

Fentanyl is used in various clinical settings, including:

  • Prior to surgery and general anesthesia.
  • During general or regional anesthesia.
  • Chronic pain management, particularly for continuous, around-the-clock pain control, using the transdermal patch.
  • Breakthrough cancer pain, managed with transmucosal or intranasal formulations.

Special Considerations

Despite there being no clinical dosage guidelines for individuals with hepatic or renal insufficiency, it is recommended to reduce the transdermal patch dose by half. Fentanyl is not recommended in cases of severe renal or hepatic dysfunction. For transmucosal and nasal formulations, no specific adjustment guidelines exist, but close monitoring is advised (Ramos-Matos et al., 2023).

Common Side Effects

Possible reactions to fentanyl are similar to other opioids and may include (Ramos-Matos et al., 2023):

  • Dry mouth and dehydration
  • Peripheral edema
  • Bradycardia and hypotension
  • Respiratory depression or shortness of breath
  • Diaphoresis
  • Nausea, vomiting, and constipation
  • Skin irritation or erythema at the patch site
  • Weakness, muscle rigidity, or sedation
  • Headache and dizziness
  • Altered mental status and CNS depression

Contraindications and Warnings

Similar to morphine, fentanyl should not be used in individuals with (Ramos-Matos et al., 2023):

  • Known hypersensitivity or allergy to fentanyl
  • Toxin-mediated diarrheal illness
  • Paralytic ileus
  • Severe respiratory disease

The transmucosal and intranasal formulations are intended only for opioid-tolerant cancer patients under specialist care and should not be used for short-term or postoperative pain.

Providers should be aware that with the transdermal patch, heat exposure, fever, or exercise can increase drug absorption and risk of toxicity. The patch should only be applied to intact skin, contain aluminum, and must be removed before MRI procedures (Ramos-Matos et al., 2023).

Drug Interactions

Potential drug interactions when administering fentanyl may include (Ramos-Matos et al., 2023):

  • Alcohol: Increases CNS depression.
  • Amphetamines: May increase fentanyl's effects.
  • Beta-agonists: May lower fentanyl serum concentrations.
  • Anticholinergics: Higher risk of constipation and urinary retention.
  • Antipsychotics: Can cause hypotension.
  • Azelastine nasal spray: Increases CNS depression.
  • Beta-blockers: May worsen bradycardia.
  • Calcium channel blockers: Increase risk of hypotension and bradycardia.
  • Hydrocodone: Increases CNS depression.
  • SSRIs: May increase serotonergic and CNS-depressant effects.
  • Zolpidem: Potentiates sedative effects.

Providers who prescribe fentanyl must be knowledgeable about its potency, pay close attention to dosage, provide adequate patient education, and monitor patients closely.

Oxycodone

Oxycodone is a known Schedule II controlled substance often prescribed for moderate to severe pain. It is available in multiple formulations, including immediate-release, controlled-release, oral concentrate, and oral solution forms. In addition, combination formulations that include acetaminophen, aspirin, or ibuprofen are often used to increase analgesic effects (Sadiq et al., 2024).

Dosing and Administration

  • Immediate-release: 5–30 mg every 4–6 hours as needed (providers should always begin with lower doses when prescribing controlled substances).
  • Safer formulations designed to prevent misuse: 5 mg and 7.5 mg tablets.
  • Controlled-release: Providers often begin prescriptions at 10 mg every 12 hours for patients requiring continuous, around-the-clock pain relief, with careful titration as needed.

Special Considerations

Providers should use caution when prescribing to individuals with any type of renal or hepatic impairment. If a creatine clearance is < 60 milliliters (mL)/min, levels of oxycodone can accumulate, making this potentially dangerous for the individual. For hepatic impairment, providers should prescribe lower doses and only titrate slowly.

In individuals with biliary diseases, such as pancreatitis, oxycodone may cause the sphincter of Oddi to spasm. In individuals with head injuries, oxycodone may increase intracranial pressure. The controlled-release formulations can lodge in the gastrointestinal tract if individuals have difficulties swallowing (Sadiq et al., 2024).

Common Side Effects

Common side effects may include (Sadiq et al., 2024):

  • Drowsiness and dizziness
  • Itching
  • Constipation
  • Nausea and vomiting

Contraindications

Oxycodone should not be used in patients with (Sadiq et al., 2024):

  • Paralytic ileus
  • Significant respiratory depression
  • Hypercarbia
  • Acute or severe bronchial asthma
  • Gastrointestinal obstruction

Drug Interactions

Several medications can increase the effects of oxycodone, such as (Sadiq et al., 2024):

  • Alcohol
  • Amphetamines
  • Anticholinergics
  • Antipsychotics
  • Azelastine nasal spray
  • Diuretics
  • Hydrocodone and hydroxyzine
  • MAOIs
  • Mirtazapine
  • Rifampin
  • SSRIs
  • Zolpidem

Hydrocodone

Hydrocodone is very similar to oxycodone and is a Schedule II controlled substance, with a short and extended-release option available. Hydrocodone often contains acetaminophen, so individuals with any kind of liver impairment should use caution, as well as those with any type of kidney disease. Hydrocodone also should not be prescribed for individuals with asthma, an ileus, respiratory depression, and more (Cofano et al., 2024).

Dosing and Administration

Immediate-release combination products:

  • Typical dosing: 5–10 mg every 4–6 hours as needed for pain.
  • Because most immediate-release formulations contain acetaminophen, providers must ensure patients do not exceed the maximum daily acetaminophen limit (4,000 mg/day from all sources).
  • As with all opioids, therapy should start at the lowest effective dose, especially in opioid-naïve individuals.

Extended-release single-agent hydrocodone:

  • Common initiation dose: 10 mg every 12 hours for continuous opioid therapy.
  • Titration should occur cautiously.

Common Side Effects

Most of the opioids have many of the same side effects, including (Cofano et al., 2024):

  • Constipation
  • Nausea and vomiting
  • Dry mouth
  • Drowsiness
  • Headache
  • Dizziness
  • Pruritus

Drug Interactions

Most of the opioids also share similar drug interactions, some of which are (Cofano et al., 2024):

  • Alcohol: Increases CNS depression.
  • Amphetamines: May increase the medication's effects.
  • Anticholinergics: May make constipation and urinary retention worse.
  • Azelastine: Increases CNS depression.
  • Diuretics: Increased risk of side effects.
  • MAOIs: Can encourage hydrocodone toxicity.
  • SSRIs: Higher risk of serotonin syndrome. 
  • Zolpidem: Increases CNS effects, can cause severe drowsiness.
  • Rifampin: May decrease hydrocodone levels.
  • CYP3A4 inhibitors
  • CYP3A4 inducers 

Special Considerations

  • Renal impairment: Hydrocodone and its metabolites can accumulate when individuals have reduced renal function.
  • Hepatic impairment: Because many hydrocodone products include acetaminophen, hepatic impairment significantly increases risk.
  • Respiratory disease: Individuals with chronic lung disease (chronic obstructive pulmonary disease [COPD], sleep apnea) may experience increased respiratory depression.
  • Gastrointestinal concerns: Combination products with acetaminophen may worsen nausea; opioid-related constipation should be anticipated and treated.
  • Traumatic brain injury: As with other opioids, hydrocodone may increase intracranial pressure and should be used with caution.

Contraindications

Hydrocodone should not be used in patients with:

  • Significant respiratory depression.
  • Acute or severe bronchial asthma without proper monitoring.
  • Known or suspected paralytic ileus.
  • Gastrointestinal obstruction.
  • Hypersensitivity to hydrocodone or formulation components.

Tramadol

Tramadol is classified as a Schedule IV controlled substance and is also prescribed for moderate to severe pain. It is available in both immediate-release and extended-release formulations (MedlinePlus, 2024).

Indications and Dosing

  • Immediate-release: Typically dosed 50–100 mg every 4–6 hours as needed, not to exceed 400 mg per day.
  • Extended-release: Initiated at 100 mg once daily, with dose increases of 100 mg every five days as needed, up to a maximum of 300 mg per day. This formulation is intended for chronic, around-the-clock pain management.

Special Considerations 

  • Providers should prescribe lower doses for older adult populations, being sure to titrate slowly. Providers should be sure not to exceed 300 mg per day for adults over the age of 75.
  • In individuals with any renal insufficiency, especially with a creatinine clearance < 30 mL/min, providers should only prescribe the immediate-release formulary, dosed 25–100 mg every 12 hours, with a maximum of 200 mg per day.
  • In individuals with any hepatic impairment, providers should limit dosing to 50 mg every 12 hours and avoid the extended-release formulation.
  • Seizure risk: Tramadol has been known to lower the seizure threshold and may trigger seizures, especially when used with SSRIs, tricyclic antidepressants, MAOIs, neuroleptics, or other opioids, or in patients with a history of seizures, CNS infection, head trauma, or substance withdrawal.

Common Side Effects

Common side effects of tramadol may include (MedlinePlus, 2024):

  • Flushing
  • Dizziness
  • Constipation, nausea, or vomiting
  • Indigestion
  • Itching
  • Headache
  • Drowsiness or insomnia
  • Weakness

Contraindications

Tramadol should not be prescribed to individuals with (MedlinePlus, 2024):

  • Known hypersensitivity to tramadol.
  • Severe hepatic or renal impairment.
  • Severe respiratory depression, asthma, or hypercapnia.
  • Acute intoxication with alcohol, opioids, hypnotics, or psychotropic agents.

Drug Interactions

Common drug interactions include (MedlinePlus, 2024):

  • Alcohol
  • Amphetamines
  • Anticholinergics
  • Antiemetics
  • Antipsychotics: Increase risk of hypotension, neuroleptic malignant syndrome, and serotonin syndrome.
  • Azelastine (nasal)
  • Carbamazepine
  • Cyclobenzaprine: Raises risk of seizures and serotonin syndrome.
  • Diuretics
  • Hydrocodone and hydroxyzine
  • MAOIs: Increase the risk of seizures and serotonin syndrome.
  • Metoclopramide: Raises the risk of serotonin syndrome and neuroleptic malignant syndrome.
  • SSRIs and tricyclic antidepressants: Increase seizure and serotonin syndrome risk.
  • Warfarin: May alter anticoagulant effects.
  • Zolpidem

Opioids in General: Dependence and Withdrawal

Prolonged use of opioids can result in physical dependence. If discontinued abruptly, withdrawal symptoms may occur, including nausea, diarrhea, anxiety, sweating, tremors, muscle aches, and chills. To minimize withdrawal, taper doses gradually when discontinuing therapy.

Side Effects of Opioid Medications

As mentioned previously, opioids carry many of the same side effects, as their mechanism of action is similar. Some of the common side effects are nausea, vomiting, itching, constipation, mental status changes, and drowsiness. In overdosages, respiratory depression may occur.

Some of the risk factors for increased side effects may include age (older adults may be more sensitive), a diet low in fiber, and others. Nursing staff and healthcare providers should provide education to individuals that increasing their water intake, activity, and fiber intake are all beneficial to reduce side effects and risks associated with opioid use. Sometimes, if individuals experience side effects, they may request additional medications. For those complaining of constipation, fiber, hydration, and activity should help, but if needed, over-the-counter stool softeners or laxatives can help (if used in moderation). If nausea is a primary complaint, some providers MAY prescribe antiemetics, but providers should use caution, as even they can have side effects. Antihistamines may be recommended if itching is reported, as long as providers have determined the itching is a side effect, and not an allergic response (Centers for Disease Control and Prevention [CDC], 2025).

Drowsiness is a very common side effect, so providers should tell individuals to avoid any other medications or substances that may also cause drowsiness. A more serious risk to opioid use is respiratory depression, but it is more commonly seen when doses are given too frequently or if higher doses are given.

The highest risk factor when considering opioid use is the potential for overdose, which is a well-known public health concern. It is because of this that naloxone became readily available in many clinics, stores, and may be prescribed in addition to opioid prescriptions.

Risk Mitigation and Monitoring

Definitions

Some medical language used in pain management and controlled-substance prescribing can be challenging for some. The following definitions help clarify some distinctions and provide a foundation for discussing safety, monitoring, and appropriate treatment planning (Donofrio, 2023).

Drug misuse is another way of saying that individuals are using prescribed medications in a manner that does not reflect the reason they were prescribed the medication. Some examples may include attempting to sell or distribute prescriptions, seeking out prescriptions from multiple healthcare providers, taking the medication to cause euphoria, or taking medication with other substances to produce various reactions (Smith et al., 2013).

Drug abuse is when an individual opts to use a drug in a manner that can be deemed harmful or inappropriate. It is well-known that controlled substances can cause individuals to become dependent, which could be psychological or physical (Smith et al., 2013).

A physical dependence is known to occur when an individual abruptly stops taking a substance and then suffers from withdrawal symptoms. Withdrawal symptoms may include tachycardia (increased heart rate), anxiety or agitation, hypertension (increased blood pressure), sweating, and mood changes (Smith et al., 2013).

A psychological dependence occurs when an individual feels they cannot function without a specific substance. It is a psychological dependence that is the typical cause of relapses and leads to difficulties in substance cessation (Smith et al., 2013).

Addiction is a more advanced version of psychological and physical dependence. When an individual experiences addiction to any type of substance, they often lose control, become unaware (or lack caring) about consequences, and may behave in ways that are uncharacteristic when noticed by family and friends (Smith et al., 2013).

Prevention of Misuse

Controlled substances always carry a risk of misuse, dependence, and overdose. Because of this, it is always best for providers to follow the Tennessee prescribing guidelines. A patient-provider relationship should always be established, with the provider performing an initial examination and assessment, as well as frequent reassessments. Treatment agreements are highly useful in these circumstances also, as they help outline responsibilities from both the provider and the patient, as well as expectations while receiving treatment (Tennessee Department of Health, n.d.).

Each state has its own prescription drug monitoring program (PDMP), and providers should utilize this anytime a patient is requesting or getting prescribed a controlled substance. This step provides prescribers with the opportunity to monitor prescriptions being ordered for the patient to help ensure safe and evidence-based prescribing is occurring.

As with any new medication or therapeutic treatment option, patients should be evaluated to determine potential risk factors and/or contraindications to treatment options. Examples of contraindications to controlled substances may include suspected or confirmed untreated addiction, uncontrolled mental illness, or a history of poor compliance behaviors.

When a provider is evaluating an individual, they should be sure to include the following in their documentation:

  • Previous or current use of opioids.
  • History or current use of substances.
  • Family history of substance abuse or mental illness.
  • Providers should also document any social, behavioral, legal, or employment data.

An important factor to consider in previous substance abuse is that people may not necessarily be automatically disqualified or excluded from treatment. These individuals may need a referral to addiction medicine or closer monitoring (Tennessee Department of Health, n.d.).

Risk Assessment Tools

Along with other assessment tools utilized in healthcare, the Opioid Risk Tool (ORT) is often used to assess for the possibility of misuse. Included in this assessment tool is determining the individual's age, family history of substance abuse, personal history of any substance use, known or suspected mental illness, and any history of sexual abuse. Depending on the answers, individuals will receive a score listed as low, moderate, or high-risk (National Institute on Drug Abuse, 2021).

Ongoing Monitoring

Controlled substances necessitate more frequent monitoring of individuals, typically every three months. As providers conduct follow-up visits, they should assess pain relief, activity level (if quality of life is impacted), how compliant the individual is on medication, if they disclose any side effects, and if there are any signs of misuse or dependency. These questions are classified as the "Five A's" (analgesia, activity, adherence, adverse effects, and addiction).

Though this could be state-specific, providers should implement regular urine drug screens if individuals are being prescribed controlled substances, as well as require a written agreement. The written agreement would help establish expectations, explain risks, discuss protocols, and hold each party accountable.

Providers also must be sure to obtain informed consent from each individual prior to prescribing any controlled substances. The consent discussion should always include risks, benefits, side effects, potential for dependency, impaired motor skills, and risk of misuse or overdose (Maumus et al., 2020).

The Role of Naloxone

Any healthcare provider who prescribes opioids should familiarize themselves with naloxone, what it is, how to prescribe it, and where to educate people on how they can find and use it. Naloxone is a medication that reverses opioid overdoses, often instantly. Injectable naloxone is most commonly seen in the acute care hospital setting. In the public, common formulas include a nasal spray and an auto-injector. Anytime someone receives naloxone, they should be transported to a local hospital for closer monitoring, especially since it can cause withdrawal symptoms if given to individuals who have a substance use disorder (National Institute on Drug Abuse, 2022).

Many prescribers will opt to order naloxone along with opioids as a precautionary measure.

Tapering Medications

Providers in Tennessee should familiarize themselves with not only clinical guidelines for opioid prescribing, but also protocols designed to reduce abrupt discontinuation of opioids and other controlled substances. Any type of controlled substance (such as opioids and benzodiazepines) that carries a high risk for addiction should never be abruptly stopped. Even if a provider has prescribed a controlled substance to an individual who is misusing their medication, a plan must be developed to safely titrate their dosage down to avoid the onset of significant withdrawal symptoms, which could become life-threatening (U.S. Food & Drug Administration [FDA], 2019). Withdrawal symptoms may include:

  • Nausea and vomiting
  • Sweating
  • Abdominal pain
  • Myalgias
  • Headache
  • Mood changes, such as irritability

Abrupt cessation of benzodiazepines is more dangerous to individuals than abrupt cessation of opioids; however, all may be potentially dangerous. In Tennessee, providers are encouraged to add medication, such as clonidine, to help reduce withdrawal symptoms.

Prescription Monitoring and Safe Prescribing

PDMPs are online databases that are used to help track controlled substances being prescribed and dispensed. Most (if not all) states have their own version of a PDMP, and all providers with prescribing rights have access. Providers are expected to check the PDMPs before writing prescriptions for controlled substances.

If a provider suspects any form of medication misuse or abuse, they have the right to act accordingly. For example, if there is a minor concern, then the provider may counsel and enhance the monitoring for the individual. If there are repeated concerns for misuse, then a provider may decide to begin tapering the individual's dose to wean them off while preventing withdrawal. In cases where providers suspect that an individual is sharing or selling their medication, they have the right to discontinue the medication altogether (CDC, 2024).

Principles of Responsible Prescribing

As in all states, Tennessee carries its own prescribing guidelines that providers are expected to follow. It is the expectation that prescribers prioritize patient safety while promoting safe healthcare, even when prescribing controlled substances. Parts of the Tennessee prescribing principles may include (Tennessee Department of Health, 2024):

  • A complete physical assessment, which includes a medical history, mental health assessment, substance use history, review of all medications, including supplements and over-the-counter medications. 
  • Determine goals of therapy and document them.
  • Search for a diagnosis and document medical necessity. 
  • Assess for a substance abuse history.
  • Discuss realistic pain management measures.
  • Check a PDMP for each person before writing any prescriptions.
  • Set the expectation of routine drug screenings.
  • Initially and consistently assess individuals for contraindications.
  • Make a written agreement for each individual that both parties sign.
  • Obtain informed consent after providing all necessary education, including risks, benefits, alternative therapies, and patient responsibilities.
  • When writing prescriptions, start with the lowest dose necessary.
  • Use caution in prescribing long-acting controlled substances.
  • Be sure to ensure that only one provider is prescribing controlled substances to each individual (the PDMP can be helpful in monitoring this).
  • Assess for side effects and determine interventions, if needed.
  • Require regular follow-up visits; ensure accuracy in documentation.
  • Remain compliant with all state and federal regulations.

Prescribers can feel confident when prescribing controlled substances as long as they follow these guidelines and aim to do what is in the best interest of all individuals, prioritizing safety.

Harm Reduction Tips

Unfortunately, providers are human and, even with the best of intentions, can make mistakes along the way. One way that providers can decrease the risk of accidental harm is to set limits on the upper dosage range of medications. Fentanyl and methadone are other high-risk medications that should be prescribed with extreme caution. Other ways that providers can use caution to help prevent harm may include (Dowell et al., 2022):

  • Pay attention to vulnerable populations, such as older adults. In older adults, providers are aware of how differently they may tolerate medications, so their starting dose may be much lower than average. 
  • Avoid prescribing opioids with other medications that can cause respiratory depression.
  • Begin at-risk individuals on a bowel regimen, since constipation is a common side effect. 
  • Watch individuals for signs of respiratory depression.
  • Avoid combining opioids with medications, such as benzodiazepines.
  • Assess for any other pertinent drug-drug interactions with each individual.

Other Controlled Substances

In addition to opioids, the Tennessee Chronic Pain Guidelines also provide insight into other controlled substances, such as benzodiazepines and barbiturates.

Benzodiazepines

Benzodiazepines are a commonly known class of controlled substances that are often prescribed for anxiety, agitation, and panic disorders. This is another medication class that carries a high risk for tolerance, dependence, and withdrawal in cases of abrupt cessation. Prescribing benzodiazepines and opioids together is often discouraged due to the increased risk of respiratory depression.

Examples of benzodiazepines include clonazepam, diazepam, and alprazolam, all of which act on the gamma-aminobutyric acid (GABA-A) receptor, which impacts our neurotransmitters. Benzodiazepines are prescribed on a regular or as-needed schedule, depending on the reason, symptomology, and individual needs. For individuals taking benzodiazepines on a regular basis, they can help with severe anxiety, but dependence is a risk. As-needed scheduling is seen in individuals who may only need a dose every now and then, for example, if someone has difficulty sleeping.

Some of the most common side effects of benzodiazepines may include drowsiness, changes in mental status, slowed motor function, confusion, risk for falls, and even weight gain. Individuals who are prescribed these medications on a long-term basis will likely develop a tolerance, necessitating the need for higher doses to achieve results (Bounds & Patel, 2024).

All individuals who are prescribed a controlled substance may reach the point where providers plan to start tapering their dosages, which is where they will slowly start to wean down their dosage.

Barbiturates

Barbiturates are most commonly prescribed for seizure disorders, with examples including pentobarbital and phenobarbital. This class of medications carries sedative-hypnotic effects and can be highly addictive, according to experts. Due to the increased risk of overdose with this class of medications, they have been replaced with benzodiazepines in many seizure treatment regimens.

The most common barbiturate still prescribed is phenobarbital, but it still requires lab monitoring. Common side effects of barbiturates may include drowsiness, euphoria, and disinhibition (Skibiski et al., 2024).

Carisoprodol

Carisoprodol is another controlled substance (Schedule IV drug class), often used in short-term increments for acute pain. Carisoprodol is a skeletal muscle relaxant, with normal dosages ranging from 250–350 mg, taken three to four times daily, with or without food. Side effects of carisoprodol may include sedation or drowsiness, headache, dizziness, and possibly seizures (Conermann & Christian, 2024).

Controlled Substances Alternatives

Non-Pharmacological Pain Management

Medication is not the only option available to help individuals with pain management. There are a variety of non-pharmacologic options that can help with pain. Commonly known options may include physical therapy, exercise, massage, heat or cold, chiropractic adjustments, psychotherapy, relaxation techniques, acupuncture, transcutaneous electrical nerve stimulation (TENS), music therapy, etc. In more advanced cases, injections, neuromodulation, spinal cord, or deep brain stimulation may also be beneficial (Sturgeon et al., 2024).

Physical and Occupational Therapy

Both physical and occupational therapy have been known to help individuals with mobility, overall function, and pain. By using their expertise, physical therapists can develop exercise and treatment plans to help strengthen muscles and improve movement. Occupational therapists can provide individuals with tools and strategies to make daily activities easier. Regular activity has been shown to reduce pain and improve mobility. Examples may include water exercise, which can be beneficial for individuals with arthritis, and aerobic activity, which can help those with conditions such as fibromyalgia (Sturgeon et al., 2024).

Movement-Based Therapies

Movement can help a lot with pain. For example, yoga or Pilates can help with flexibility and balance while also helping reduce back discomfort. There are various levels that individuals can choose based on their tolerance, with beginner classes being a good starting point (Sturgeon et al., 2024).

Massage and Temperature

Therapeutic and deep tissue massage can help decrease pain by loosening tight muscles and improving circulation. Heat has been around forever, as it is known to relax muscles and increase blood flow. Cold helps with swelling and muscle spasms. Some individuals benefit from switching between heat and cold.

Psychological and Behavioral

Pain is not always just physical; the mind can also play a role in how pain is felt. Cognitive behavioral therapy (CBT) is one therapy that may be used to help people learn coping skills and change thought patterns that impact the way they feel pain. Relaxation options such as guided imagery or breathwork can help relax the body, while distraction can help people focus on things other than pain (Rahman et al., 2023).

Electrical Neuromodulation

TENS is an intervention that uses low-voltage electrical currents that get passed through the skin to block pain signals before they reach the brain. It can be helpful for various types of pain, but it does come with some warnings. TENS units should not be used on individuals with pacemakers, arrhythmias, or during pregnancy. Biofeedback can be an option to help teach body awareness and control of functions like heart rate or muscle tension. Some tend to think that biofeedback exercises may help with pain reduction (Wang & Doan, 2024).

Acupuncture

Acupuncture is when trained professionals use fine needles to insert into various trigger points within the body to stimulate natural pain-relieving mechanisms and promote balance in the body's energy flow. Many individuals have reported significant improvements in both acute and chronic pain conditions after receiving acupuncture (Wang et al., 2025).

Music Therapy

Music therapy promotes relaxation, reduces stress, and alters pain perception. It may trigger the release of natural pain-relieving chemicals like endorphins, while also improving mood and overall well-being.

Interventional Procedures

For those whose pain continues despite conservative care, interventional options such as targeted injections, nerve ablation, or spinal and deep-brain stimulation may be considered. These techniques work to disrupt or modulate pain signals for longer-term relief (Rahman et al., 2023).

Types of Pain

Two types of pain that providers should be knowledgeable about include nociceptive pain and neuropathic pain. Nociceptive pain is often the result of inflammation or some type of tissue injury or damage. This type of pain may be managed by using opioid or non-opioid analgesics. Neuropathic pain can often be caused by nerve damage or neuropathy. Providers may often prescribe types of antidepressants, gabapentin, or even pregabalin in these cases (Wang & Doan, 2024).

Non-Opioid Pharmacological Pain Management

Chronic pain is tough to manage, and even with good intentions, treatment does not always hit the mark. A surprising number of individuals still do not get adequate relief. Part of the problem is figuring out what meds work well together, what dose is safe, and how often something can realistically be given. Some medications are meant to be taken every day, while others are only for when symptoms flare. Side effects make the decision-making even harder (Rahman et al., 2023).

Opioids are not the only option. Non-opioids, muscle relaxers, certain antidepressants, and topical products are all used pretty regularly. A lot of providers end up using a mix of things, hoping to cover different angles of the pain instead of relying on one single medication (Rahman et al., 2023).

A good plan still starts with a thorough assessment. Current medical conditions matter, but so does anything from the past—old injuries, surgeries, chronic illnesses, and mental health history. For example, someone dealing with pain and depression might respond better to a medication that can help with both. It is also the provider's responsibility to review allergies, current medications, and anything that could cause a serious interaction before deciding what to prescribe (Rahman et al., 2023).

Acetaminophen

Acetaminophen is often used early in the treatment of pain because it is easy to find and generally well-tolerated. However, even though it is sold over the counter, it still carries risks. The main concern is liver damage, which can occur when someone takes more than the recommended amount or uses it along with alcohol. This is why providers should make sure individuals know how much they are taking and recognize that acetaminophen is included in many other products.

Most adults take 325–650 mg every four to six hours, and some may take 1,000 mg at a time depending on the situation. The daily limit is 4,000 mg. Many combination products (like cold and flu medicines) contain acetaminophen. The FDA also requires a black box warning on combination products because of the potential for severe liver injury. Since acetaminophen is commonly paired with opioid medications, it is important to remind patients not to take extra over-the-counter products that contain it as well (Schwenk, 2025).

Non-Steroidal Anti-Inflammatory Drugs

Non-steroidal anti-inflammatories (NSAIDs) are another common group of analgesics that can be used in combination products and are available over the counter. NSAIDs are often used for arthritis, sprains, tendonitis, and other mild to moderate sources of pain. Commonly known NSAIDs include ibuprofen, naproxen, diclofenac, and aspirin (Rahman et al., 2023).

The mechanism of action of NSAIDs is that they block the enzymes COX-1 and COX-2, which produce prostaglandins that promote inflammation and cause pain. The COX-1 enzyme helps protect the stomach lining; working against it can cause bleeding and irritation. This is one of the reasons why aspirin should never be given to children under the age of 17.

Though NSAIDs and acetaminophen are often used together, NSAIDs have higher risks than acetaminophen in terms of side effects. Long-term use of NSAIDs is generally discouraged in anyone, but especially older populations or individuals with increased risk factors, such as a history of peptic ulcers, kidney disease, actively taking corticosteroids, and more.

Side effects that are commonly associated with NSAID use may include stomach upset, constipation, ulcers, and even kidney or cardiac complications. Individuals taking NSAIDs should avoid taking them on an empty stomach, and many should take them with a proton pump inhibitor to help protect the stomach lining.

Individuals on any type of blood thinners or anticoagulants should avoid NSAIDs, if possible, as well as individuals with any kind of kidney disease (Schwenk, 2025).

Antidepressants in Pain Management

Chronic pain can show up for a lot of reasons—neuropathy, fibromyalgia, or even depression. Because of that, some antidepressants are used to help manage certain types of pain (Rahman et al., 2023).

Tricyclic Antidepressants

Tricyclic antidepressants (TCAs) may be used as an adjunct therapy for pain management, with commonly known ones including amitriptyline and nortriptyline. TCAs should not be prescribed to individuals with past cardiac conditions (Wang & Doan, 2024).

Serotonin-Norepinephrine Reuptake Inhibitors

Serotonin-norepinephrine reuptake inhibitors (SNRIs) may also help with chronic neuropathy and some musculoskeletal pain. Well-known SNRIs may include duloxetine and venlafaxine. Both of these have been approved to assist with individuals complaining of chronic back pain, fibromyalgia, neuropathy, and arthritis (Wang & Doan, 2024).

Antiepileptic Agents

Commonly known anticonvulsants are often prescribed for more than just seizure management; they can be used in pain management. Gabapentin and pregabalin are the most commonly known medications in this class and are beneficial in helping with neuropathies, anxiety, fibromyalgia, and more (Wang & Doan, 2024).

Miscellaneous Agents

In addition to the opioid and non-opioid options and antidepressants, there are also topical options and muscle relaxants that have been said to be beneficial in chronic pain management. Topical medications, such as lidocaine, may be given in a patch form to help with pain. Muscle relaxers, such as cyclobenzaprine, can also be beneficial. Providers need to pay special close attention to providing education on the risks and side effects of any of these medications (Wang & Doan, 2024).

Case Study #1: Melissa

Melissa is a 45-year-old female whose primary complaint is chronic neck and shoulder pain related to cervical spondylosis with radiculopathy. Melissa first received this diagnosis a few years ago after being injured while at work. When the provider asked Melissa to describe her pain, she described it as burning and radiating down her left arm with occasional numbness and tingling in her fingers. Her current pain level is 8/10, and her pain gets worse anytime she is on her computer or sits for prolonged periods of time.

Melissa currently works as a medical billing specialist, but misses several days of work each month because of her pain. She denies changes to her bowel or bladder function, fever, or recent infection. Sleep is poor, and she complains of feeling more fatigued.

Melissa's past medical history consists of anxiety disorder and gastroesophageal reflux disease (GERD). She takes pantoprazole 40 mg daily for reflux and buspirone 10 mg twice daily for anxiety. She has no history of substance abuse and drinks alcohol only occasionally. She quit smoking five years ago.

Melissa has tried multiple treatments, including physical therapy, acupuncture, heat therapy, TENS, and medications such as acetaminophen, naproxen, and muscle relaxants, but still lives in chronic pain. Melissa had tried gabapentin 300 mg three times daily, but it caused excessive drowsiness. She has also used topical diclofenac with minimal benefit.

When conducting a neurological exam, the provider notes some weakness in her left triceps, diminished sensation in the left thumb, and a positive Spurling's test. Reflexes are symmetric, and there is no muscle atrophy. A recent MRI confirmed moderate degenerative changes at C5–C6 with mild foraminal narrowing.

According to the ORT, Melissa scored low risk for misuse. Per the guidelines, she signed an opioid treatment agreement and was counseled about safe use, secure storage, and potential side effects.

Melissa's provider prescribed tramadol 50 mg every six hours as needed (maximum four per day) for one week. After five days, she called the office complaining of continued pain, along with nausea and a headache. The provider discontinued the tramadol and prescribed duloxetine 30 mg daily, with instructions to increase to 60 mg after two weeks.

A few weeks later, Melissa had her one-month follow-up and reported some improvement in her pain and mood, and that she had missed fewer days of work. The provider opted to add a topical lidocaine patch for breakthrough pain and referred Melissa to a pain management specialist for a possible cervical epidural injection.

Since Melissa was not on any opioids, the provider skipped over the discussion on a bowel regimen. She was also educated on posture, ergonomics in the workplace, and exercises to prevent further degeneration. Three months later, Melissa reports her pain level averaging 4–5/10, her sleep improving, and an improved quality of life overall. She continues duloxetine 60 mg daily and uses lidocaine patches occasionally.

Case Study #2: Michael

Michael is a 52-year-old male who has a primary complaint of shoulder and upper arm pain after suffering a rotator cuff injury and frozen shoulder. Michael states his pain began approximately 18 months ago after a fall at work while he was lifting a heavy piece of equipment. When asked to describe his pain, Michael described it as aching and throbbing, with occasional sharp flares when he reaches overhead or behind his back. He currently rates his pain as 7/10, which gets worse with any movement or when the weather gets colder.

When performing an assessment and gathering his medical history, Michael disclosed a history of hyperlipidemia, type 2 diabetes, and hypertension, all of which are controlled by prescribed medications. Michael reports taking metformin, atorvastatin, and lisinopril daily. Michael denies any allergies or past surgeries, as well as any alcohol or substance use history.

Michael states he takes ibuprofen 800 mg three times daily (TID) and acetaminophen 1000mg TID for his pain, but states they do not help. After trying these medications for several months, his previous provider gave him hydrocodone/acetaminophen 5/325mg every six hours to take as needed, but stated they did not help much either.

On exam, Michael has a restricted range of motion in the right shoulder, in addition to tenderness over the anterior shoulder joint and upper arm. Strength testing shows mild weakness secondary to pain. There is no swelling, deformity, or erythema.

Michael had a recent MRI, which showed partial-thickness tearing of the supraspinatus tendon and mild adhesive capsulitis.

After reviewing the guidelines, the provider checked the prescription monitoring system and did not feel there was anything concerning. Urine drug screening was negative for any non-prescribed substances. Michael completed the ORT and scored as low risk for misuse.

The APRN discussed a plan that included reducing opioid usage as they are able, while also improving function. The hydrocodone was discontinued, and they prescribed duloxetine 30 mg daily, which could be titrated to 60 mg after two weeks for combined neuropathic pain and mood support. The provider also administered a corticosteroid injection into the right shoulder joint and submitted a referral to physical therapy for stretching and strengthening exercises.

After four weeks, Michael came to his follow-up appointment and reported less pain and improved sleep, rating his pain at 4/10. His wife was also present and stated she noticed increased activity and engagement at home. The duloxetine was continued at 60 mg, and a topical diclofenac gel was added for use twice daily.

After three months, Michael transitioned off all opioids, continued the duloxetine and topical NSAIDs, and regained most of his shoulder mobility. He also began a light exercise routine, lost 12 pounds, and stated that he "finally feels like himself again."

Conclusion

Pain management continues to evolve as healthcare professionals learn more about addiction, regulatory expectations, and the importance of a multimodal, patient-centered approach. The information covered in this course is intended to strengthen clinical decision-making, reinforce safety practices, and support providers as they navigate the complexities of prescribing controlled substances. Integrating these principles into daily practice can help improve outcomes and reduce preventable harm.

Select one of the following methods to complete this course.

Take TestPass an exam testing your knowledge of the course material.
OR
No TestComplete a course evaluation.

Implicit Bias Statement

CEUFast, Inc. is committed to furthering diversity, equity, and inclusion (DEI). While reflecting on this course content, CEUFast, Inc. would like you to consider your individual perspective and question your own biases. Remember, implicit bias is a form of bias that impacts our practice as healthcare professionals. Implicit bias occurs when we have automatic prejudices, judgments, and/or a general attitude towards a person or a group of people based on associated stereotypes we have formed over time. These automatic thoughts occur without our conscious knowledge and without our intentional desire to discriminate. The concern with implicit bias is that this can impact our actions and decisions with our workplace leadership, colleagues, and even our patients. While it is our universal goal to treat everyone equally, our implicit biases can influence our interactions, assessments, communication, prioritization, and decision-making concerning patients, which can ultimately adversely impact health outcomes. It is important to keep this in mind in order to intentionally work to self-identify our own risk areas where our implicit biases might influence our behaviors. Together, we can cease perpetuating stereotypes and remind each other to remain mindful to help avoid reacting according to biases that are contrary to our conscious beliefs and values.

References

  • Bounds, C. G., & Patel, P. (2024). Benzodiazepines. In StatPearls. StatPearls Publishing. Visit Source.
  • Brown, K. S. & Bruns, D. L. (2020). Guidance on psychological assessment and management of chronic pain during the COVID-19 crisis. American Psychological Association. Visit Source.
  • Centers for Disease Control and Prevention. (2024). Prescription Drug Monitoring Programs (PDMP). Centers for Disease Control and Prevention. Visit Source.
  • Centers for Disease Control and Prevention. (CDC). (2025). Basics About Prescription Opioids. Centers for Disease Control and Prevention. Visit Source.
  • Chang, C. D., Saidinejad, M., Atanelov, Z., Dietrich, A. M., Lam, S. H., Rose, E., Ruttan, T., Shahid, S., Stoner, M. J., Sulton, C., Chumpitazi, C. E., & ACEP Pediatric Emergency Medicine Committee. (2021). Emergency department strategies to combat the opioid crisis in children and adolescents. Journal of the American College of Emergency Physicians Open, 2(4), e12512. Visit Source.
  • Cofano, S., Patel, P., & Yellon, R. (2024). Hydrocodone. In StatPearls. StatPearls Publishing. Visit Source.
  • Conermann, T., & Christian, D. (2024). Carisoprodol. In StatPearls. StatPearls Publishing. Visit Source.
  • Donofrio, J. (2023). Opioids: Understanding Addiction Versus Dependence. Hospital for Special Surgery. Visit Source.
  • Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022). CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. Morbidity and Mortality Weekly Report. Recommendations and Reports, 71(3), 1–95. Visit Source.
  • Lopez, M. J., Preuss, C. V., & Tadi, P. (2023). Drug Enforcement Administration Drug Scheduling. In StatPearls. StatPearls Publishing. Visit Source.
  • Maumus, M., Mancini, R., Zumsteg, D. M., & Mandali, D. K. (2020). Aberrant Drug-Related Behavior Monitoring. Ochsner Journal, 20(4), 358–361. Visit Source.
  • MedlinePlus. (2024). Tramadol. National Library of Medicine. Visit Source.
  • Murphy, P. B., Patel, P., & Barrett, M. J. (2025). Morphine. In StatPearls. StatPearls Publishing. Visit Source.
  • National Institute on Drug Abuse. (2021). Opioid Risk Tool – OUD (ORT-OUD). National Institutes of Health. Visit Source.
  • National Institute on Drug Abuse. (2022). Naloxone DrugFacts. National Institutes of Health. Visit Source.
  • Ofoegbu, A., & B Ettienne, E. (2021). Pharmacogenomics and Morphine. Journal of Clinical Pharmacology, 61(9), 1149–1155. Visit Source.
  • Rahman, S., Kidwai, A., Rakhamimova, E., Elias, M., Caldwell, W., & Bergese, S. D. (2023). Clinical Diagnosis and Treatment of Chronic Pain. Diagnostics, 13(24), 3689. Visit Source.
  • Ramos-Matos, C. F., Bistas, K. G., & Lopez-Ojeda, W. (2023). Fentanyl. In StatPearls. StatPearls Publishing. Visit Source.
  • Sadiq, N. M., Dice, T. J., & Mead, T. (2024). Oxycodone. In StatPearls. StatPearls Publishing. Visit Source.
  • Schwenk, E. (2025). Nonopioid Pharmacotherapy for acute pain in adults. UpToDate. Visit Source.
  • Skibiski, J., Patel, P., & Abdijadid, S. (2024). Barbiturates. In StatPearls. StatPearls Publishing. Visit Source.
  • Smith, S. M., Dart, R. C., Katz, N. P., Paillard, F., Adams, E. H., Comer, S. D., Degroot, A., Edwards, R. R., Haddox, D. J., Jaffe, J. H., Jones, C. M., Kleber, H. D., Kopecky, E. A., Markman, J. D., Montoya, I. D., O'Brien, C., Roland, C. L., Stanton, M., Strain, E. C., Vorsanger, G., … Dworkin, R. H. (2013). Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain, 154(11), 2287–2296. Visit Source.
  • Stretanski, M. F., Stinocher, S., & Grandhe, S. (2025). Pain Assessment. In StatPearls. StatPearls Publishing. Visit Source.
  • Sturgeon, J. A., Cooley, C., & Minhas, D. (2024). Practical approaches for clinicians in chronic pain management: Strategies and solutions. Best practice & research. Clinical Rheumatology, 38(1), 101934. Visit Source.
  • Tennessee Board of Nursing. (2024). Advanced Practice Registered Nurses. Tennessee Board of Nursing. Visit Source.
  • Tennessee Department of Health. (n.d.). Substance Misuse Prevention. Tennessee Department of Health. Visit Source.
  • Tennessee Department of Health. (2024). Tennessee Chronic Pain Guidelines. Tennessee Department of Health. Visit Source.
  • Tennessee Department of Health. (2025). Controlled Substance Monitoring Database. Tennessee Department of Health. Visit Source.
  • The Joint Commission (TJC). (2021). What are the key concepts organizations need to understand regarding the pain management requirements? The Joint Commission. Visit Source.
  • U.S. Food & Drug Administration (FDA). (2019). FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering. U.S. Food & Drug Administration. Visit Source.
  • Volkow, N. D., & Blanco, C. (2021). The changing opioid crisis: development, challenges and opportunities. Molecular Psychiatry, 26(1), 218–233. Visit Source.
  • Wang, Y., Aaron, R., Attal, N., & Colloca, L. (2025). An update on non-pharmacological interventions for pain relief. Cell Reports. Medicine, 6(2), 101940. Visit Source.
  • Wang, J., & Doan, L. V. (2024). Clinical pain management: Current practice and recent innovations in research. Cell Reports. Medicine, 5(10), 101786. Visit Source.